BMY
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$60.22
−0.58%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- $1.11
- Revenue estimate
- $12.7B
Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- $2.04
- EPS estimate
- $1.59
- Revenue actual
- $13.0B
- Revenue estimate
- $11.8B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +12.3%
- Revenue beats (12Q)
- 11
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $65
- PT range
- $41 – $78
- Analysts
- 12
5 Buy6 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | $1.11 | $1.35 | Beat 21.62% | $13.1B |
| Jul 30, 2026 | $1.59 | $2.04 | Beat 28.14% | $13.0B |
| Apr 30, 2026 | $1.42 | $1.58 | Beat 11.27% | $11.5B |
| Feb 5, 2026 | $1.23 | $1.26 | Beat 2.44% | $12.5B |
| Oct 30, 2025 | $1.52 | $1.63 | Beat 7.24% | $12.2B |
| Jul 31, 2025 | $1.09 | $1.46 | Beat 33.94% | $12.3B |
| Apr 24, 2025 | $1.49 | $1.80 | Beat 20.81% | $11.2B |
| Feb 6, 2025 | $1.47 | $1.67 | Beat 13.61% | $12.3B |
| Oct 31, 2024 | $1.49 | $1.80 | Beat 20.81% | $11.9B |
| Jul 26, 2024 | $1.62 | $2.07 | Beat 27.78% | $12.2B |
| Apr 25, 2024 | -$4.41 | -$4.40 | Beat 0.23% | $11.9B |
| Feb 2, 2024 | $1.53 | $1.70 | Beat 11.40% | $11.5B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026